These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31393188)

  • 21. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
    Khattab MA; Eslam M; Shatat M; Abd-Aalhalim H; Mousa YI; Samir F; Aly H; Shaker O; Shaker Y
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):59-65. PubMed ID: 22457861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
    Deltenre P; Louvet A; Lemoine M; Mourad A; Fartoux L; Moreno C; Henrion J; Mathurin P; Serfaty L
    J Hepatol; 2011 Dec; 55(6):1187-94. PubMed ID: 21703195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
    J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.
    Schmidt FP; Zimmermann T; Wenz T; Schnorbus B; Ostad MA; Feist C; Grambihler A; Schattenberg JM; Sprinzl MF; Münzel T; Galle PR
    Int J Cardiol; 2018 Nov; 271():296-300. PubMed ID: 30077529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
    Bortoletto G; Scribano L; Realdon S; Marcolongo M; Mirandola S; Franceschini L; Bonisegna S; Noventa F; Plebani M; Martines D; Alberti A
    J Viral Hepat; 2010 Jul; 17(7):475-80. PubMed ID: 19878535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hirooka Y; Toyoda H; Kumada T; Hattori M; Katano Y; Goto H
    J Viral Hepat; 2018 Dec; 25(12):1446-1451. PubMed ID: 29993164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
    Huang JF; Dai CY; Yu ML; Huang CF; Huang CI; Yeh ML; Yang JF; Hou NJ; Hsiao PJ; Lin ZY; Chen SC; Shin SJ; Chuang WL
    Liver Int; 2011 Sep; 31(8):1155-62. PubMed ID: 21745292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
    Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
    Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis.
    Hu JH; Chang ML; Liu NJ; Yeh CT; Huang TJ
    Exp Ther Med; 2019 Nov; 18(5):3568-3578. PubMed ID: 31602234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism.
    Sparvoli JMH; Sparvoli AC; de Carvalho Dumith S; Pereira AA; de Paula ALM; Garcia L; Belarmino V; da Hora VP; de Martínez AMB; Gonçalves CV
    Arch Endocrinol Metab; 2023 Mar; 67(3):314-322. PubMed ID: 36468927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
    Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
    J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
    J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.
    Degasperi E; Valenti L; Aghemo A; De Francesco R; Rumi M; Soffredini R; Donnici L; Cheroni C; Fargion S; Zanoni V; Orsi E; Colombo M
    Antivir Ther; 2014; 19(8):747-53. PubMed ID: 24523350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals.
    Nevola R; Rinaldi L; Zeni L; Sasso FC; Pafundi PC; Guerrera B; Marrone A; Giordano M; Adinolfi LE
    JGH Open; 2020 Aug; 4(4):713-721. PubMed ID: 32782961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C.
    Adinolfi LE; Rinaldi L; Marrone A; Giordano M
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):595-597. PubMed ID: 30047799
    [No Abstract]   [Full Text] [Related]  

  • 40. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
    Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M
    Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.